|
Press Releases |
|
|
|
Wednesday, May 15, 2024 |
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
Monday, May 13, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
Thursday, April 18, 2024 |
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
Wednesday, April 17, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」(一般名:ペランパネル水和物、海外製品名:「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
Wednesday, April 3, 2024 |
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
Monday, April 1, 2024 |
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
Friday, March 29, 2024 |
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Virturo Elite Club: Unlock Exclusive Wealth-Building Opportunities for High-Net-Worth Individuals
Dec 21, 2024 09:30: JST
|
|
|
Pathwizz Redefines Trust in Digital Transactions with Award-Winning Support and Verified Platforms 'Wizz Support'
Dec 21, 2024 09:00: JST
|
|
|
Virturo Elite Club: Unlock Exclusive Wealth-Building Opportunities for High-Net-Worth Individuals
Dec 21, 2024 08:00 HKT/SGT
|
|
|
Pathwizz Redefines Trust in Digital Transactions with Award-Winning Support and Verified Platforms 'Wizz Support'
Dec 21, 2024 07:00 HKT/SGT
|
|
|
VAP Group's Global AI Show Explores the Future of AI with Over 3,000 Participants
Dec 20, 2024 23:05: JST
|
|
|
VAP Group's Global AI Show Explores the Future of AI with Over 3,000 Participants
Dec 20, 2024 22:46 HKT/SGT
|
|
|
n-hop technologies Limited and OneAsia Network Limited Partner to Revolutionize Data Transfer and Networking Solutions
Dec 20, 2024 21:40 HKT/SGT
|
|
|
AEON Credit Revenue Up 9.4% to HK$1,304.6 Million for First Nine Months of FY2024/25
Dec 20, 2024 21:30 HKT/SGT
|
|
|
Hong Kong Vocational Education Service in Joint Construction of the 'Belt and Road' Vocational Education Symposium
Dec 20, 2024 21:20 HKT/SGT
|
|
|
Huatai Securities Achieves MSCI ESG AAA Rating, the Highest Rating among Global Investment Banks
Dec 20, 2024 21:15 HKT/SGT
|
|
|
The finest places to live, work, and thrive in Asia are celebrated at the 19th PropertyGuru Asia Property Awards Grand Final
Dec 20, 2024 21:10 HKT/SGT
|
|
|
From Visionary Talks to Futuristic Robots: VAP Group's Global Blockchain Show Dazzles Dubai
Dec 20, 2024 20:22 HKT/SGT
|
|
|
ASEAN Ceramics & ASEAN Stone 2024 Reaches New Heights with Record-Breaking Visitor Turnout
Dec 20, 2024 20:20 HKT/SGT
|
|
|
Trio AI 建立人工智能超级计算(AISC)卓越伙伴生态格局
Dec 20, 2024 19:17 HKT/SGT
|
|
|
Trio AI Establishes Partnership Ecosystem for Artificial Intelligence Super Computing (AISC)
Dec 20, 2024 18:33 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|